Inotuzumab Ozogamicin in Indian Patients with B-Cell Acute Lymphoblastic Leukemia

Pronamee Borah,Vivek Mohan,Sachin Jain,Varun Capoor,Rahul Naithani

DOI: https://doi.org/10.1007/s12288-024-01881-0

2024-09-25

Indian Journal of Hematology and Blood Transfusion

Abstract:There is scarcity of data on utility of inotuzumab ozogamicin (InO) in relapsed refractory acute lymphoblastic leukemia in India. This is a retrospective study. Twelve patients (3 children) with a median age of 22.5 years (8–80 Years) were evaluated. Two patients received upfront InO therapy due to poor general condition. Four patients received IO due to persistent MRD positivity. Six patients had active disease of which 5 were multiply relapsed. Six patients received single-agent InO. Median number of cycles were 2 (1–6). All received inotuzumab on scheduled days and there was no treatment delay due to cytopenia. Ten patients (83%) achieved measurable residual disease (MRD) negative complete remission (CR). Seven of these ten patients became MRD-negative after 1 cycle only. All MRD-positive patients converted to MRD-negative remission. Four patients underwent allogeneic bone marrow transplant. Two patients continued standard maintenance therapy. Six patients succumbed. The median follow-up of the entire cohort is 10.7 months (2–32 months). Five out of twelve (41.6%) patients are alive and in MRD-negative remission at a median follow-up of 22 months (11–32 months). Inotuzumab ozogamicin is an effective agent for inducing deep remissions in patients with B-cell acute lymphoblastic leukemia.

hematology